Pediatric Rheumatology · 2011 · 20 citations · 0 references
Life SciencesImmunologyPharmacotherapyAutoimmunityImmunotherapyRheumatologyAnti-inflammatory PharmacologyImmune-mediated Inflammatory DiseasesInflammatory ArthritisInflammatory Disease PharmacotherapyJoint DiseaseJuvenile Idiopathic ArthritisImmune-mediated ArthritisInterleukin-6 InhibitionInterleukin-6 InhibitorsJuvenile Arthritis
Purpose Treatment options for sJIA are limited. Excessive IL-6 production has been implicated in several manifestations of this disease. In a previous Japanese study, TCZ, an IL-6 receptor inhibitor, improved arthritis and systemic features of patients with refractory sJIA. We present efficacy and safety of TCZ in patients with active sJIA who were treated for ≥52 wks in the global, 3-part, 5-yr, phase 3, multicenter TENDER study. Methods